Research programme: muscle disorders therapeutics - Regeneron
Latest Information Update: 04 Nov 2017
Price :
$50 *
At a glance
- Originator Regeneron Pharmaceuticals
- Class Monoclonal antibodies; Proteins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Musculoskeletal disorders
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Musculoskeletal-disorders in USA (Parenteral)
- 21 Aug 2007 Early research is ongoing
- 29 May 2006 Early research in Musculoskeletal disorders in USA (unspecified route)